Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
0.907
+0.007 (0.72%)
At close: Nov 22, 2024, 4:00 PM
0.910
+0.003 (0.29%)
After-hours: Nov 22, 2024, 7:45 PM EST
Ocugen Employees
Ocugen had 65 employees as of December 31, 2023. The number of employees decreased by 19 or -22.62% compared to the previous year.
Employees
65
Change (1Y)
-19
Growth (1Y)
-22.62%
Revenue / Employee
$72,308
Profits / Employee
-$786,831
Market Cap
264.34M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Zynex | 1,100 |
Lifecore Biomedical | 524 |
Anika Therapeutics | 357 |
Poseida Therapeutics | 330 |
Lyell Immunopharma | 224 |
Precigen | 202 |
NeuroPace | 171 |
Atai Life Sciences | 83 |
OCGN News
- 2 days ago - Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease - GlobeNewsWire
- 3 days ago - Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 14 days ago - Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Ocugen Provides Business Update with Third Quarter 2024 Financial Results - GlobeNewsWire
- 15 days ago - Ocugen Secures $30 Million in Debt Funding - GlobeNewsWire
- 25 days ago - Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 - GlobeNewsWire
- 4 weeks ago - Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease - GlobeNewsWire
- 5 weeks ago - Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results - GlobeNewsWire